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ABSTRAK
Tujuan: untuk menilai remisi imunologi setelah kondisi eutiroid tercapai paska pengobatan PTU dosis 
rumatan pada pasien penyakit Graves. Metode: penelitian ini merupakan penelitian intervensi dengan 
rancangan pre-post pada 25 orang pasien penyakit Grave yang berobat ke poli khusus endokrinologi metabolik 
RSUP Dr. M. Djamil Padang dan mendapat PTU selama 12 bulan. Darah pasien diperiksa pada awal dan 
akhir pengobatan untuk menilai remisi imunologis yang dicerminkan oleh kadar IL-4 serum. Hasil: setelah 
terapi rumatan, ditemukan penurunan bermakna kadar T3 (2,29±0,57 nmol/L vs. 1,87±0,34 nmol/L, p<0,05), 
penurunan bermakna kadar T4 (118,15±25,99 nmol/L vs. 94,15±23,76 nmol/L, p<0,05), peningkatan bermakna 
kadar TSH serum (0,379±0,548 vs. 0,859 ± 0,990, p<0,05) dan penurunan bermakna kadar IL-4 (12,23±5,74 vs. 
3,84±0,42, p<0,05) meskipun penurunan ini belum mencapai batas normal. Kesimpulan: pengobatan dengan 
propiltiourasil dosis rumatan dapat menurunkan parameter hormonal secara bermakna hingga mencapai kondisi 
eutiroid namun tidak dapat menurunkan parameter imunologis (IL4) sampai batas normal.
Kata kunci: respons hormonal, imunologis, kadar IL4, penyakit Graves.
ABSTRACT
Aim: to assess immunologic remission in patients with Graves’ disease following euthyroid condition at 
the end of treatment with maintenance dose of PTU. Methods: this is an intervention study using one-group 
pre-post design. Subjects were 25 Graves‘ disease patients visiting Metabolic Endocrinology Clinic at Dr. 
M.Djamil hospital Padang and met the inclusion criteria. Patients were given PTU treatment for 12 months. 
Blood samples were taken at the beginning and at the end of treatment to determine immunological remission 
reflected by differences in IL-4serum levels. Results: after maintenance therapy, we found significant decrease 
of T3 levels (2.29±0.57 nmol/L vs. 1.87±0.34 nmol/L, p<0.05), significant decrease of T4 levels (118.15±25.99 
nmol/L vs. 94.15±23.76 nmol/L, p<0.05), significant increase of TSH levels (0.379±0.548 vs. 0.859±0.990, 
p<0.05) and significant decreased levels of IL-4 (12.23±5.74 vs. 3.84±0.42, p<0.05). The IL-4 level, however, 
did not decrease to the normal levels. Conclusion: PTU administration in maintenance dose can significantly 
reduce thyroid hormonal parameter levels down to euthyroid condition, but cannot reduce immunological 
parameter (IL4) to normal limit. 
Key words: hormonal, immunologic, interleukin-4, Graves’ disease.
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INTRODUCTION
Graves’ disease is the most common disease 
causing hyperthyroidism, accounting for 60-80% 
of all cases.1 It is an autoimmune disease that 
has multifactorial origins including interaction 
of endogenous fragile factors with genetic and 
environmental factors. IgG antibodies bind to and 
activate thyrotropin receptor (thyroid stimulating 
antibody TSAB) causes follicular hypertrophy 
and hyperplasia resulting in enlargement of the 
gland and enhances hormon production.2,3 It is 
suspected that autoimmune disorder plays a role 
because of low clonal T suppressor cells (Ts) that 
are genetically responsible for the production of 
TSAB. 
Interleukin-4 stimulates isotype-secreting 
Cells Immunoglobulin G3 (IgG3-SCS), which 
are associated with the severity of Graves’ 
disease. In addition, TRAb levels can also 
alter IgG1 that can stimulate the production of 
TRAb.9-11
There are two methods in the treatment of 
Graves’ disease using anti-thyroid drugs. One is 
based on titration, treatment starts with a large 
dose (initial phase) and then based on clinical/
laboratory result, the dose was lowered to reach 
the lowest dose which still results in a state of 
euthyroid (maintenance phase). Treatment length 
may vary but usually lasts over 12-18 months The 
other is referred to as block-substitution, where 
treatment starts with a large dose continuously 
and in case of hypothyroidism, the coupled 
substitution therapy is done with thyroxine 
hormone to get back into euthyroid.12 Abraham 
et al.13 found titration method as effective as 
block-substitution method. Treatment that has 
minimum side effects should be the first choice 
in starting the treatment.
It has been know that treatment of Graves 
‘disease with anti-thyroid drugs either in the 
initial phase or maintenance phase will usually 
yield euthyroid conditions, but the effect on 
immunological conditions need further studied. 
Several studies have been conducted to find the 
effect of anti-thyroid against immunological 
parameter such as IL-4. Komiya et al.14 reported 
that serum levels of IL-4 was not detected after 
18 months of treatment with metimazol. Marina15 
in her study of 25 patients with Graves’ disease 
reported significant decrease in serum levels of 
IL-4 after initial treatment with PTU, although 
it did not reach normal levels. She showed that 
euthyroid condition that has occurred after the 
initial treatment with PTU was not followed by 
immunological remission (normal levels of IL-4).
This study aims at revealing the effect of 
PTU against IL-4 levels after maintenance phase 
of hyperthyroid treatment. The importance of 
this study is that it will identify immunological 
remission of Graves’ disease.
METHODS 
This is an intervention study using one-group 
pre-post design. The research was conducted in the 
clinic and ward of internal medicine department 
Dr.M. Djamil hospital Padang. Measurements of 
T3, T4, TSH were performed at the Imunoserologi 
Laboratory of Dr. M. Djamil Hospital Padang 
and IL-4 was examined in Imunoserologi Health 
Center laboratory of West Sumatra Province. 
Subjects were patients with Graves’ disease who 
had received initial treatment with PTU and met 
inclusion criteria: had received initial treatment 
before maintenance therapy of PTU, aged ≥ 15 
y.o., and agreed to participate in the research. 
Exclusion criteria were: any accompanying 
allergic diseases, pregnant, liver disease/liver 
dysfunction, heart failure, and taking hormonal 
contraception. Sample size for this study was 
determined by formula of one group intervention 
pre and post design. Alfa was determined 0.05, β 
was 0.2, and the mean difference was expected to 
be 0.5 mmol/L. Based on the formula, 25 persons 
were recruited as subject.
Subjects who met inclusion criteria were 
checked for baseline parameters consisting of T3, 
T4, TSH, and IL-4 levels. All subjects received 
prophylthiouracil (PTU) produced by PT. 
Indofarma with a dose of 3x50 mg for 9 months 
(maintenance therapy) until total initial dosage 
and maintenance therapy for 12 months. They 
were clinically evaluated every month to assess 
drug compliance and adverse effects. After 3 
months (month 6 of PTU treatment), serum levels 
of IL-4 were examined. After 9 months (month 
12 of PTU treatment), the levels of T3, T4, TSH 
and serum IL-4 were re-examined. Finally, we 
analyze the data to answer whether euthyroid 
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condition after maintenance therapy with PTU 
will be followed by immunological remission 
through examination of serum levels of IL-4.
Levels of T3, T4 and TSH were measured 
using a reagent kit from Roche. Measurements 
used ECL method immuchemiluminescence 
tool from Roche Cobas e 411. Serum levels 
of IL-4 were measured using reagent kit of 
human IL-4 products from Bender Med System. 
Measurements used Elisa method.
Data were analyzed to compare the condition 
before and after the intervention. Shapiro Wilk 
normality test was used to view whether the data 
were normally distributed. If data were normally 
distributed, then analysis was followed by paired 
t test, but if the distribution was not normal, data 
transformation was done in advance. If data 
transformation resulted in a normal distribution, 
paired t test was used, but if the transformation 
did not produce normal distribution, then the 
Wilcoxon test was used.
RESULTS
PTU treatment at maintenance dose 
significantly lowered IL4 levels, but the reduction 
did not reach normal levels. (Figure 1)
Meanwhile, this treatment was associated 
with significant lower T3 levels, from 2.19±0.57 
mmol/L to 1.87±0.34 mmol/L (Figure 2). The 
same effect was found for T4 levels where there 
was a significant decrease in T4 levels from 
118.15 ± 25.99 mmol/L to 94.15 ± 23.76 mmol/L 
(Figure 3).
In conjunction with the decrease of T3 and 
T4, treatment with a maintenance dose of PTU 
produced a significant increase in TSH levels. 
TSH levels before PTU maintenance therapy 
ranged from 0.01 to 2.14 IU/ml with a mean 
of 0.379±0.548 IU/ml. TSH levels after PTU 
maintenance therapy ranged from 0.05 to 3.90 
IU/ml with a mean of 0.859±0.990 but only 
17 (68%) subjects reached normal levels. The 
remaining 8 (32%) subjects did not reach normal 
levels (Figure 4).
DISCUSSION
We had conducted an intervention study 
using one-group pre-post design. Assessment of 
Table 1. Subjects characteristics
Characteristics n (%)
Age
 - <30 9 (36)
 - 30-40 5 (20)
 - >40 11 (44)
Sex
 - male 7 (28)
 - female 18 (72)
Smoking
 - yes 5 (20)
 - No 20 (80)
Family History 
 - yes 3 (12)
 - No 22 (88)
Struma Grade 
 - Grade I 3 (12)
 - Grade II 15 (60)
 - Grade III 7 (28)
Onset 
 - <6 months 14 (56)
 - 6-12 months 6 (24)
 - >12 months 5 (20)
Figure 1. Levels of IL-4 at initial, 6 month of therapy, and 
after maintenance therapy
Figure 2. T3 serum levels at initial and after maintenance 
therapy
Vol 46 • Number 4 • October 2014               Immunologic and hormonal effects on the propiltiourasil treatment
317
had history of smoking. Smoking is a risk factor 
for Graves’ disease by RR 2.62. Smoking spurs 
hypoxia and nicotine in cigarettes could spur an 
increase in HLA-DR expression that can both 
stimulate and worsen inflammatory reaction.19 It 
is stated that smoking is one of the independent 
risk factors for recurrence after medical therapy.20
Serum levels of IL-4 before PTU maintenance 
therapy ranged from 2.4 to 27.8 pg/ml with a 
mean of 12.23±5.74 pg/ml. In all subjects the 
levels of serum IL-4 before maintenance therapy 
with PTU did not reach normal levels, although at 
the same time the levels of T3 and T4 has reached 
normal levels. This might indicate that initial 
treatment before PTU maintenance therapy did 
not yield immunological remission following 
euthyroid condition.
Serum levels of IL-4 after PTU maintenance 
therapy ranged from 3.16 to 5.3 pg/ml with a 
mean of 3.84±0.42 pg/ml. After therapy with 
maintenance dose of PTU, mean levels of IL-4 
significantly decreased (p<0.05). No subjects 
reached normal levels although at the same 
time levels of T3 and T4 has reached normal 
levels. The same condition indicates that PTU 
maintenance therapy did not yield immunological 
remission following euthyroid condition.
Komiya et al.14 found that serum levels 
of IL-4 was not detected after 18 months of 
treatment with metimazol. Li21 in his study of 
42 Graves’ patients got serum levels of IL-4 
significantly higher than the 40 control patients 
before treatment. After 12 weeks of treatment with 
anti-thyroid drugs, serum levels of IL-4 downed 
near normal. Wei22 in his study obtained serum 
levels of IL-4 significantly increased in 33 patients 
with Graves ophtalmopathy before treatment 
compared to 35 control patients. After 1 month 
of treatment, he found decreasing levels of IL-4 
serum of patients with Graves ophtalmopathy. 
Our study found that the IL-4 levels decreased 
drastically during the first six months of treatment. 
However, no study has been able to explain the 
process and the condition comprehensively.
T3 levels before PTU maintenance therapy 
ranged from 1.38 to 3.1 nmol/L with a mean 
of 2.19±0.57 nmol/L. All subjects were within 
normal limit. T3 levels after PTU maintenance 
therapy ranged from 1.31 to 2.63 nmol/L with a 
Figure 3. T4 serum levels at initial and after maintenance 
therapy
Figure 4. TSH serum levels at initial and after maintenance 
therapy
the effects of PTU dose in maintenance therapy 
was reflected on levels of IL4, T3, T4 and TSH 
before and after PTU therapy.
There were 25 subjects with Graves’ disease 
included in this study, with range of age of 16-
64 y.o. Subject’s age range in this study was 
similar to Komiya et al.14 who showed that out 
of 107 patients with Graves’ disease there were 
patients who were 17-67 y.o. Graves’ disease is 
most common found in patients aged <40 years, 
although 15% may occur in patients aged> 60 
years.
In this study, female subjects (72%) were 
more frequent than males (28%). This is similar 
with the research by Humaidi MA.16 that out of 
28 patients with Graves’ disease, 78.57% were 
female and 21.43% were male. Hartono17 also 
showed that out of 30 Graves’ patients, 90% 
were female and 10% were male. Graves’ disease 
occurs ten times more frequent in women than in 
men. The influence of female hormone estrogen 
causes the risk of Graves’ thyrotoxicosis in 
women being larger than males.18
This study also found that 20% of the subjects 
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mean of 1.87±0.34 nmol/L. This result showed 
significant decrease (p<0.05) but remained 
within the normal limit. Nordling MA et al.23 
obtained mean of T3 levels after medical therapy 
as 1.8 nmol/L. Another study found that relapse 
frequently occurs in patients with Graves’ initial 
high T3 levels.24
T4 levels before maintenance therapy of PTU 
ranged from 75 to 178 nmol/L with a mean of 
118.15±25.99 nmol/L. All subjects were within 
normal limit. T4 levels after PTU maintenance 
therapy ranged from 66.02 to 164.47 nmol/L 
with a mean of 94.15±23.76 nmol/L. All subjects 
showed significant decrease (p<0.05) but 
remained within normal limit.
Komiya et al.14 obtained T4 levels after 
therapy with 18 months of metimazol as 109±22 
nmol/L in the group with increased IgE, and 
106±21 nmol/L in the group with normal IgE. 
Relapse frequently occurs in patients with 
Graves’ initial high T4 levels.
This study also found elevated levels of TSH 
due to antithyroid therapy, but only 17 out of 25 
subjects reached normal levels and the other 8 
subjects did not. The levels of TSH often remains 
high, and it may take many months or even 
years to recover because of prolonged pituitary 
suppression by thyroid hormone (lazy pituitary).
Komiya et al.14 obtained a mean TSH levels 
after therapy as 2.18±1.61 mU/L in the group 
with increased IgE and 2.35±2.33 mU/L in the 
group with normal IgE. Yamada et al.9 found 
mean TSH levels after 2-year therapy with 
metimazol as 1.06±0.91 μIU/ml.
The mechanism of remission from 
autoimmune disorders in patients with Graves is 
considered as a direct result of immunosuppressive 
tionamid drugs. Many clinical studies have 
demonstrated that remission during therapy with 
anti-thyroid drugs is not dependent on the dose 
and type (methymazol and PTU) but dependent 
on immunological regulatory that led patients to 
become euthyroid. In addition, the presence of 
individual response to the autoimmune process 
also affects the response of treatment.24,25
CONCLUSION
PTU maintenance dose can reduce IL-4 
levels significantly but not to the normal levels. 
PTU therapy for 12 months gives a good response 
to the hormonal status of Grave’s patients, yet it 
cannot suppress immunological activity to the 
normal stage.
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